The time to offer treatments for COVID-19

Autor: David Peng, Preet M. Chaudhary, Fred R. Sattler, Marc Rendell, Leland Shapiro, Mika Turkia, Raphael Thomadsen, Denise Brennan-Rieder, Daniel G. Arkfeld, Binh Ngo, Gilles Hayem, Joseph Varon, Pierre Kory, Michael P. Dubé, Oriol Mitjà, Vito M. Campese, Iraldo Bello Rivero, Antonio Lobo-Ferreira, Cristina Mussini, Eivind H Vinjevoll, Daniel O. Griffin, Nicolas Peschanski, Gino K. In, Paul E. Marik, April W. Armstrong, Glenn Ehresmann, David Sawcer, Maria Carmela Piccirillo, Vicente Soriano, Marco Confalonieri, Diana L. Hanna, Stephen Ditmore, Rajkumar Dasgupta, Jose Iglesias, Ivan F H Hung, Miroslaw Smogorewski, Neha Nanda

Publikováno v: Re-Unir. Archivo Institucional de la Universidad Internacional de La Rioja
instname
Expert Opinion on Investigational Drugs
article-version (VoR) Version of Record
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Introduction: COVID-19 has several overlapping phases. Treatment has focused on the late stage of the disease in hospital. Yet, the continuation of the pandemic is by propagation of the disease in outpatients. The current public health strategy relie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef7a31f6cffb8f837c6e4a70a630c55
https://doi.org/10.1080/13543784.2021.1901883